Author/Authors :
GALVIS, Virgilio Centro Oftalmologico Virgilio Galvis - Floridablanca, Colombia , TELLO, Alejandro Centro Oftalmologico Virgilio Galvis - Floridablanca, Colombia , PARRA, M. Margarita Centro Oftalmologico Virgilio Galvis - Floridablanca, Colombia , MERAYO-LLOVES, Jesus Centro Oftalmologico Virgilio Galvis - Floridablanca, Colombia , LARREA, Jaime Centro Oftalmologico Virgilio Galvis - Floridablanca, Colombia , JULIAN RODRIGUEZ, Carlos Centro Oftalmologico Virgilio Galvis - Floridablanca, Colombia , Anthony CAMACHO, Paul Centro Oftalmologico Virgilio Galvis - Floridablanca, Colombia
Abstract :
Atropine has been used for more than a century to arrest myopia progression. Compelling evidence of its protective effect has been reported in well-designed clinical studies, mainly performed during the last two decades. However, its exact mechanism of action has not been determined. Experimental findings have shown that the mechanism is not related to accommodation, as was thought for decades. A review of the published literature revealed a significant amount of evidence supporting its safety and efficacy at a concentration of 1.0%, and at lower concentrations (as low as 0.01%).
